NCT00384774View on ClinicalTrials.gov

A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine

PHASE2CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Migraine

Interventions

DRUG

Lasmiditan

Administered as intravenous infusion

DRUG

Placebo

Administered as intravenous infusion

Trial Locations (3)

Unknown

Helsinki

Essen

Leiden

Sponsors

Collaborators (1)

CoLucid Pharmaceuticals

All Listed Sponsors

collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT00384774 - A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter